Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis.
Danahay H, Gosling M, Fox R, Lilley S, Charlton H, Hargrave JD, Schofield TB, Hay DA, Went N, McMahon P, Marlin F, Scott J, Vile J, Hewison S, Ellam S, Brown S, Sabater J, Kennet G, Lightowler S, Collingwood SP.
Danahay H, et al. Among authors: brown s.
Eur J Med Chem. 2024 Nov 8;282:117040. doi: 10.1016/j.ejmech.2024.117040. Online ahead of print.
Eur J Med Chem. 2024.
PMID: 39561495